SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-18-186765
Filing Date
2018-06-07
Accepted
2018-06-07 16:03:05
Documents
8
Period of Report
2018-06-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d421697d8k.htm 8-K 20796
2 EX-1.1 d421697dex11.htm EX-1.1 220082
3 EX-4.1 d421697dex41.htm EX-4.1 59892
4 EX-5.1 d421697dex51.htm EX-5.1 12406
5 EX-99.1 d421697dex991.htm EX-99.1 7669
6 EX-99.2 d421697dex992.htm EX-99.2 8914
7 GRAPHIC g421697g0607104558562.jpg GRAPHIC 4945
8 GRAPHIC g421697g0607104804286.jpg GRAPHIC 4945
  Complete submission text file 0001193125-18-186765.txt   344820
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 18886503
SIC: 2834 Pharmaceutical Preparations